Loading...

Ultra-LEAF™ Purified anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_LEAF_021606
C57BL/6 mouse splenocytes were stained with LEAF™ purified CD3e (clone 145-2C11) (filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by anti-Armenian hamster IgG FITC.
  • 145-2C11_LEAF_021606
    C57BL/6 mouse splenocytes were stained with LEAF™ purified CD3e (clone 145-2C11) (filled histogram) or Armenian hamster IgG isotype control (open histogram), followed by anti-Armenian hamster IgG FITC.
Compare all formats
Cat # Size Price Quantity Check Availability Save
100360 25 mg 1408 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100371 50 mg 2354 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100372 100 mg 3383 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100339 100 µg 63 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100340 1 mg 164 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100359 5 mg 583 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level
Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested
IHC-F, IP, Activ, Block, WB, ICC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume or 100 µl of whole blood.  It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Additional Product Notes

Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  2. Jairaman A, et al. 2021. Bio Protoc. 11:e4170. PubMed
  3. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  4. Kwon H, et al. 2022. Sci Immunol. 7:eabq2630. PubMed
  5. Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed
  6. Chen J, et al. 2022. Neoplasma. 69:1129. PubMed
  7. Krishnamurty AT, et al. 2022. Nature. 611:148. PubMed
  8. Zhang H, et al. 2022. J Clin Invest. 132: . PubMed
  9. Sato A, et al. 2022. Biol Pharm Bull. 45:1798. PubMed
  10. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  11. Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed
  12. Romine KA, et al. 2023. Leukemia. 37:580. PubMed
  13. Pitmon E, et al. 2023. PLoS One. 18:e0280916. PubMed
  14. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  15. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  16. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  17. Mirji G, et al. 2022. Sci Immunol. 7:eabn0704. PubMed
  18. Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed
  19. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  20. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  21. Guo L, et al. 2023. Sci Signal. 16:eadd4900. PubMed
  22. Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed
  23. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  24. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  25. Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed
  26. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  27. Wang T, et al. 2023. Commun Biol. 6:613. PubMed
  28. Roy S, et al. 2023. J Clin Invest. 133:. PubMed
  29. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  30. Duong–Ly KC, et al. 2018. J Cell Sci. 131:17. PubMed
  31. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  32. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  33. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  34. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  35. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  36. Donado CA, et al. 2020. Cell Reports. 31(1):107466. PubMed
  37. Wang W, et al. 2020. Cell Rep. 107936:32. PubMed
  38. Zhao X, et al. 2021. Int J Oral Sci. 13:31. PubMed
  39. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  40. Krone A, et al. 2022. Sci Rep. 218:. PubMed
  41. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  42. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  43. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  44. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  45. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  46. Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed
  47. Dong L, et al. 2017. Sci Rep. 10.1038/srep36598. PubMed
  48. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  49. Hoover DB, et al. 2020. Int Immunopharmacol. 106359:81. PubMed
  50. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  51. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  52. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  53. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  54. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  55. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  56. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  57. Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed
  58. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  59. Gandhi VD, et al. 2022. J Clin Invest. 132:. PubMed
  60. Herrera FG, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  61. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  62. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  63. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  64. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  65. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  66. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  67. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  68. Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed
  69. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  70. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  71. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  72. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  73. Woo MS, et al. 2021. J Exp Med. :218. PubMed
  74. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
  75. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  76. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  77. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  78. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  79. Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed
  80. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  81. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  82. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  83. Zhang Z, et al. 2021. Front Immunol. 12:699478. PubMed
  84. Pandit M, et al. 2022. Exp Mol Med. 54:1214. PubMed
  85. Guo Z, et al. 2022. Neurobiol Pain. 12:100096. PubMed
  86. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  87. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  88. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  89. Wang F, et al. 2021. Nat Commun. 12:1378. PubMed
  90. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_2800555 (BioLegend Cat. No. 100360)
AB_2800555 (BioLegend Cat. No. 100371)
AB_2800555 (BioLegend Cat. No. 100372)
AB_2800555 (BioLegend Cat. No. 100339)
AB_2800555 (BioLegend Cat. No. 100340)
AB_2800555 (BioLegend Cat. No. 100359)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD3epsilon
Specificity Alt (DOES NOT SHOW ON TDS):
CD3ε
App Abbreviation (DOES NOT SHOW ON TDS):
FC,IHC-F,IP,Activ,Block,WB,ICC
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Go To Top Version: 4    Revision Date: 10.04.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account